Seeking Alpha

S & N ceases U.S. distribution of Ranasys

  • Smith & Nephew (SNN -1.7%) temporarily ceases distribution of the Renasys Negative Pressure Wound Therapy product line in the U.S. The stoppage is per instructions from the FDA that Renasys needs new 510(k) regulatory clearance because of design enhancements that have been made to the product. The company has filed the relevant paperwork and awaits the agency's action.
  • Renasys' U.S. sales represented <5% of global Advanced Wound Management revenue in 2013.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: